Alentis is a clinical stage biopharma focused on discovering and developing novel therapies for the treatment of unmet fibrotic diseases.
In the US and Europe alone, about 45% of deaths can be attributed to fibrotic disorders. Fibrosis affects nearly all tissues and organ systems such as the liver, kidneys, and lungs.
Advanced liver fibrosis and associated cirrhosis is the fastest-growing indication for liver transplantation in the United States.
While multiple investigational agents target mechanisms that impact the earlier metabolic stages of the fibrosis development, Alentis is targeting clinically advanced liver fibrosis associated with different etiologies through inhibition of Claudin-1, a recently discovered therapeutic target for organ fibrosis.
ALE.F02 is a highly selective anti-Claudin-1 mAb that recognizes pathological overexpressed and conformation-dependent Claudin-1 epitopes in fibrotic disease.
In preclinical studies, the lead molecule ALE.F02 modulates the function of non-junctional Claudin-1, preventing, and possibly reversing, the growth of fibrotic tissue within the liver and kidney by changing the plasticity of key cell types mediating fibrosis.
Safety studies in non-human primates have supported translatability of the approach into patients.
Alentis Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of life-threatening fibrotic diseases.
The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).
The company's lead candidates are monoclonal antibodies that are highly selective for Claudin-1, a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers.
It also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis of other tissues including the kidney and lung.
Alentis is headquartered in Basel's pharma-biotech hub in Switzerland with a subsidiary for R and D in Strasbourg, France.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review